Properties (52)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology company
|
| gptkbp:acquisition |
Dopamine Therapeutics
|
| gptkbp:awards |
Best Places to Work
Top Workplaces |
| gptkbp:budget |
available online
|
| gptkbp:CEO |
gptkb:Kevin_Gorman
|
| gptkbp:clinicalTrials |
ongoing
Phase 3 multiple candidates published results |
| gptkbp:collaborations |
gptkb:UCLA
gptkb:Harvard_University gptkb:Stanford_University academic institutions |
| gptkbp:community_engagement |
patient advocacy
health initiatives |
| gptkbp:employees |
over 500
|
| gptkbp:focus |
neurological diseases
endocrine diseases |
| gptkbp:focus_area |
chronic pain
endocrine disorders CNS disorders |
| gptkbp:founded |
1992
|
| gptkbp:headquarters |
gptkb:San_Diego,_California
|
| https://www.w3.org/2000/01/rdf-schema#label |
Neurocrine Biosciences
|
| gptkbp:investmentFocus |
available online
in R&D |
| gptkbp:partnerships |
gptkb:Pfizer
gptkb:Lundbeck AbbVie Sage Therapeutics |
| gptkbp:patentType |
Ingrezza (2017)
Orilissa (2018) Vyepti_(2020) |
| gptkbp:philanthropy |
education initiatives
research funding healthcare_access |
| gptkbp:products |
Ingrezza
Orilissa Vyepti |
| gptkbp:publications |
peer-reviewed journals
|
| gptkbp:research_areas |
neuroinflammation
movement disorders neurodegeneration psychiatric disorders neuropsychiatry hormonal disorders |
| gptkbp:revenue |
$500 million (2022)
|
| gptkbp:sells |
NBIX
|
| gptkbp:stockExchange |
gptkb:NASDAQ
NBIX |
| gptkbp:website |
www.neurocrine.com
|